Hence, it is likely that anti-tumour responses in treated mice are linked to the accumulated CD11b+ DCs that could activate CD4 T cells to produce IL-2, necessary for the efficient generation of CD8 effector T cells. The gene discussed is CD8A; the disease is neoplasm.